Quantcast

Latest Nephrotic syndrome Stories

2010-11-22 05:30:00

DENVER, Nov. 22, 2010 /PRNewswire/ -- On November 20 at the American Society of Nephrology (ASN) 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment...

2010-11-22 05:30:00

DENVER, Nov. 22, 2010 /PRNewswire/ -- On November 20 at the American Society of Nephrology 43rd Annual Meeting, Columbia University Assistant Professor of Clinical Medicine Andrew Bomback, MD, presented results from a patient case series assessing the potential therapeutic value of H.P. Acthar® Gel (repository corticotropin injection) as a treatment for patients with nephrotic syndrome, a kidney disorder characterized by excessive loss of urinary protein. Initial data...

2010-11-17 08:02:00

Local charity underwrites important kidney research JUPITER, Fla., Nov. 17, 2010 /PRNewswire-USNewswire/ -- The Halpin Foundation and the American Society of Nephrology (ASN) are proud to highlight the research advances in membranous nephropathy made possible by the Halpin Foundation-ASN Research Grant, created to help young faculty develop independent research careers. This award provides recipients transition funding toward successful application for an NIH RO1 grant. The Halpin...

2010-11-16 05:30:00

ANAHEIM, Calif., Nov. 16, 2010 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the Maxim Group Growth Conference at 4:00 p.m. ET on Thursday, November 18, 2010 at the Grand Hyatt Hotel in New York. Don M. Bailey, President and Chief Executive Officer, will review the Company's business strategy and recent corporate developments. Attendance at this conference is by invitation only. A live audio and slides webcast of Questcor's...

2010-11-10 18:21:54

The Halpin Foundation and the American Society of Nephrology (ASN) proudly highlight the research advances in membranous nephropathy made possible by The Halpin Foundation-ASN Research Grant, created to help young faculty develop independent research careers. This award provides recipients transition funding toward successful application for an NIH RO1 grant. Elena Torban, PhD (McGill University Faculty of Medicine), the 2008 recipient of The Halpin Foundation-ASN Research Grant, recently...

2010-11-03 05:01:00

UNION CITY, Calif., Nov. 3, 2010 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that the commercial launch is now underway for H.P. Acthar® Gel (repository corticotropin injection) as monotherapy for the treatment of Infantile Spasms (IS) in infants and children under the age of two years. This new Acthar indication was approved by the U.S. Food and Drug Administration (FDA) on October 15, 2010. Acthar provides an important treatment...

2010-10-28 15:05:00

ANAHEIM, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today reported financial results for the quarter ended September 30, 2010. Net sales totaled $31.3 million and net income was $11.5 million or $0.18 per diluted common share for the quarter ended September 30, 2010. The Company's financial performance was driven primarily by an increase in net sales for Acthar in the treatment of acute exacerbations of multiple sclerosis (MS). Acthar net sales...

2010-10-25 05:30:00

ANAHEIM, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the 21st Annual Oppenheimer Healthcare Conference at 1:00 p.m. ET on Wednesday, November 3, 2010 at The Waldorf-Astoria Hotel in New York. Don M. Bailey, President and Chief Executive Officer, will review the Company's business strategy and recent corporate developments. Attendance at this conference is by invitation only. A live audio and slides...

2010-10-15 08:29:00

ANAHEIM, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced the U.S. Food and Drug Administration (FDA) has approved Questcor's supplemental new drug application (sNDA) for H.P. Acthar® Gel (repository corticotropin injection) in the treatment of infantile spasms (IS), an ultra-rare orphan disorder affecting approximately 2,000 American children annually. IS is a devastating and potentially life-threatening form of...

2010-09-20 05:30:00

UNION CITY, Calif., Sept. 20 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at The Grand Hyatt Hotel in New York. Don M. Bailey, President and Chief Executive Officer, will discuss the Company's business strategy and historical financial performance at 3:30 p.m. Eastern Time. Attendance at this conference is by invitation only. A live audio and slides webcast of...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'